Shawky Heba A, Essawy Marwa M
Department of Preventive Dental Sciences, Periodontics Division, College of Dentistry, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Oral Pathology Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt.
Saudi Dent J. 2023 Jul;35(5):515-524. doi: 10.1016/j.sdentj.2023.04.002. Epub 2023 Apr 17.
Periodontitis is a complex chronic inflammatory disease aggravated in immunosuppressed patients. However, adjuvant therapies can alleviate severe inflammation and slow down disease progression.
To evaluate the efficacy of myricitrin, a herbal flavonoid glycoside, in reducing immunosuppression-associated periodontitis and compare its effects with that of alendronate on alveolar bone regeneration.
Fifty albino Wistar rats were randomly allocated to the control, periodontitis, immunosuppressant, myricitrin, and alendronate groups. Ligature-associated periodontitis was induced in all groups, except the control group. Cyclosporin A (CsA) was administered subcutaneously in the immunosuppressant group for immunosuppression. The myricitrin group received CsA and myricitrin, whereas the alendronate group received CsA and alendronate. The therapeutic efficacies of myricitrin and alendronate were compared histologically, morphometrically, and biochemically.
Myricitrin reversed bone destruction in the periodontitis and immunosuppressant groups. Morphometrically, myricitrin showed comparable improvements to alendronate in terms of gaining more bone area to 49.4 ± 4.6 and 59.5 ± 2%, respectively ( < 0.001 in relation to the untreated periodontitis group). Concomitantly, myricitrin increased osteoblast count significantly to 28.4 ± 4.7 closer to the 34.5 ± 2.4 count in the alendronate group ( < 0.001 compared with 22.5 ± 2.6 count of the immunosuppressant group). Moreover, myricitrin restored the serum calcium to 9.4 ± 0.6 mg/dL and alkaline phosphatase up to 112.9 ± 2.9 IU/L, which were almost normal levels similar to the control cohort ( > 0.05).
Myricitrin showed beneficial effects in counteracting bone resorption in subjects with immunosuppression-associated periodontitis. Its efficacy in slowing down disease progression was comparable to that of alendronate.
牙周炎是一种复杂的慢性炎症性疾病，在免疫抑制患者中会加重。然而，辅助治疗可以减轻严重炎症并减缓疾病进展。
评估杨梅素（一种草药黄酮苷）在减轻免疫抑制相关牙周炎方面的疗效，并将其与阿仑膦酸钠对牙槽骨再生的影响进行比较。
将50只白化Wistar大鼠随机分为对照组、牙周炎组、免疫抑制剂组、杨梅素组和阿仑膦酸钠组。除对照组外，所有组均诱导结扎相关牙周炎。免疫抑制剂组皮下注射环孢素A（CsA）进行免疫抑制。杨梅素组接受CsA和杨梅素，而阿仑膦酸钠组接受CsA和阿仑膦酸钠。从组织学、形态计量学和生物化学方面比较杨梅素和阿仑膦酸钠的治疗效果。
杨梅素逆转了牙周炎组和免疫抑制剂组的骨破坏。形态计量学上，杨梅素在增加骨面积方面显示出与阿仑膦酸钠相当的改善，分别达到49.4±4.6%和59.5±2%（与未治疗的牙周炎组相比，P<0.001）。同时，杨梅素使成骨细胞计数显著增加至28.4±4.7，更接近阿仑膦酸钠组的34.5±2.4计数（与免疫抑制剂组的22.5±2.6计数相比，P<0.001）。此外，杨梅素将血清钙恢复至9.4±0.6mg/dL，碱性磷酸酶恢复至112.9±2.9IU/L，这几乎是与对照组相似的正常水平（P>0.05）。
杨梅素在对抗免疫抑制相关牙周炎患者的骨吸收方面显示出有益作用。其在减缓疾病进展方面的疗效与阿仑膦酸钠相当。
